Analytical Research Development, Merck & Co., Inc., Rahway, NJ, USA.
Analytical Research Development, Merck & Co., Inc., Rahway, NJ, USA.
J Pharm Biomed Anal. 2024 Jan 20;238:115788. doi: 10.1016/j.jpba.2023.115788. Epub 2023 Oct 11.
Streptococcus pneumoniae bacterial infection causes mortality in both adults and infants. To mitigate the impact of the disease, several Pneumococcal conjugate vaccines (PCVs) have been manufactured for the U.S. market, including the recent approval of the 15-valent PCV Vaxneuvance™ from MSD. These vaccines demonstrate high efficacy for both the adult and pediatric dose. These PCVs contain multiple unique serotypes in the final, formulated vaccine product, and identifying a specific polysaccharide, in the presence of other serotypes, is a critical quality attribute that must be demonstrated through analytical testing. Here we describe the development and qualification of an identity assay using an automated capillary western system, called Simple Western, implementing a multi-valent system suitability sample (SSS) to determine individual polysaccharide components. The assay was optimized through rigorous analytical development and was successfully qualified for use in the clinical release of the PCV.
肺炎链球菌细菌感染可导致成人和婴儿死亡。为了减轻该疾病的影响,已经为美国市场生产了几种肺炎球菌结合疫苗(PCV),包括默沙东最近批准的 15 价 PCV Vaxneuvance™。这些疫苗对成人和儿童剂量均具有高效性。这些 PCV 在最终的配方疫苗产品中包含多种独特的血清型,并且在存在其他血清型的情况下,鉴定特定的多糖是必须通过分析测试证明的关键质量属性。在这里,我们描述了使用自动化毛细管西部系统(称为 Simple Western)开发和鉴定身份检测的过程,该系统采用多价系统适用性样本(SSS)来确定各个多糖成分。通过严格的分析开发对该检测进行了优化,并成功获得批准,可用于 PCV 的临床放行。